Trial result ·
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This paper gives 5-year results of the TRANSCEND NHL 001 trial. Patients had large B-cell lymphoma that had returned or not responded. It also used data from a separate long-term follow-up study. In all, 345 patients had cells collected and 270 got lisocabtagene maraleucel. 257 could be judged for efficacy.
What they found
Median overall survival was 27.5 months in those judged for efficacy. It was 15.2 months in all who had cells collected. Median disease-specific survival was 67.8 months in the first group. Among 84 patients in long-term follow-up, median survival was not reached. Most deaths came within 2 years after the infusion. No new safety signals were seen. Late severe infections and second cancers were rare.
What it means for patients
The authors say the data support the potential of this treatment for these patients.
Why it is not certain yet
The 84 patients in long-term follow-up were alive at study completion. That group may differ from all patients. The abstract does not describe a comparison group. Survival figures differed between the groups counted. The abstract gives no figures on quality of life.
The registered trials
The paper names these trials from a public trial registry. Each trial page shows who the trial is for, its sites and its status.
Source
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.
PubMed · PMID 42237652We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Diffuse large B-cell lymphoma publications